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Abstract 
Inhibition of mushroom tyrosinase was observed with synthetic dihydropyrano[3,2-
b]chromenediones. Among them, DHPC04 displayed the most potent tyrosinase inhibitory 
activity with a Ki value of 4µM, comparable to the reference standard inhibitor kojic acid. A 
kinetic study suggested that these synthetic heterocyclic compounds behave as competitive 
inhibitors for the L-DOPA binding site of the enzyme. Furthermore, molecular modeling 
provided important insight into the mechanism of binding interactions with the tyrosinase 
copper active site.   
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Introduction 
Melanin is the major cellular component observed in many species of animals, plants, 
fungi and bacteria (1). In humans it is responsible for skin color and protection against 
radiation (2). However, abnormal accumulation of melanin induces pigmentation disorders, 
among which, the most deadly form of skin cancer can form (i.e. melanoma) (3). Melanin 
develops in pigment cells called melanocytes due to the overproduction of melanin, the 
protective tanning pigment in the skin (4).  
 
Melanin biosynthesis is conducted in melanocytes, found in the basal layer of the 
epidermis and controlled by a binuclear copper enzyme called tyrosinase (TYR) (EC 
1.14.14.1) (5). TYR is ubiquitous and catalyzes the oxidation of both monophenols (cresolase 
or monophenolase activity) and o-diphenols (catecholase or diphenolase activity) into 
reactive o-quinones. In addition, it is a rate-limiting enzyme for controlling the production of 
melanin. The melanogenesis begins with the conversion of the amino acid L-tyrosine to L-
3,4-dihydroxyphenylalanine (L-DOPA) catalyzed by tyrosinase (TYR) (6). Therefore, the 
regulation of the TYR activity is directly connected with melanin biosynthesis. 
 
TYR is classified structurally as a type-3 copper protein in which each active-site 
copper ion is coordinated by three histidine residues (7) (Figure 1).  In general, the TYR 
inhibition mechanism is frequently based on both specific TYR inhibitors and specific TYR 
inactivators (8). A large set of potent TYR inhibitors from natural and synthetic resources 
have been reported during the last few years (8-12). Kojic acid (KA) is a well-known TYR 
inhibitor and is widely used as a popular cosmetic skin-lightening ingredient. Its capacity to 
chelate copper ion at the active site of the enzyme may consistently explain its inhibitory 
effect (13). However, it only showed slight inhibitory activity against pigmentation within 
intact melanocytes or in clinical assays (14). Therefore, it remains necessary to find new TYR 
inhibitors with higher activity and without off target side effects. 
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Figure 1. Catalytic site of TYR. The
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Figure 2. The 4H-chromene scaffold (left) and the pyrano[3,2-b] motif (right). 
 
Materials and Methods 
Experimental Section 
Materials 
TYR of mushroom (M.W. 128 kDa), L-DOPA, dimethylsulfoxide (DMSO) and KA 
were purchased from Sigma-Aldrich.  
TYR Activity 
TYR-inhibition activity of the DHPC01-04 compounds (Table 1) were performed by 
using L-DOPA as a substrate according to Kubo and co-workers (22) with slight 
modification. Incubation was carried out at 160 µl of different concentrations of the substrate 
L-DOPA, 20 µl (2.4 U) of enzyme mushroom tyrosinase, 20 µl of KA and different 
concentrations of DHPCs (25, 50 and 100µM).  All solutions were prepared in Phosphate 
Buffered Saline (PBS) pH 7.2.  
The reaction was initiated by addition of enzyme to all wells simultaneously, which 
was measured over the first 5 minutes in the microplate reader (ELx800, BioTek) with a 490 
nm filter.  Furthermore, a control reaction was also performed by incubating the enzyme with 
KA or DHPCs in the absence of the substrate to demonstrate that there was no variation in 
absorbance over time. 
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Determination of Inhibition Constant (Ki) 
The mode of inhibition on the enzyme was assayed by incubation of the different 
concentrations of L-DOPA (0; 0.25; 0.5; 0.75; 1.0; 2.0; 3.0 and 4.0 mM) and inhibitors (0; 
0.001; 0.025; 0.05; 0.1; 0.2; 0.4; 0.8 and 1.6 mM). The kinetic parameters (Km, Vmax and Ki) 
were determined with the GraphPad Prism®5.0 software, according to the following 
equations: 
I. Competitive Inhibition: 
ܭ௠ಲ೛೛ = ܭ௠ · ൬1 +
ܫ
ܭ௜൰ 
ܻ = ௠ܸ௔௫ · ܺܭ௠ + ஺ܺ௣௣ 
II. Mixed Inhibition: 
௠ܸ௔௫ಲ೛೛ = ௠ܸ௔௫൤1 + ܫሺߙ · ܭ௜ሻ൨
 
ܭ݉௠௔௫ಲ೛೛ =
ܭ௠ · ቀ1 + ܫܭ௜ቁ
൤1 + ܫሺߙ · ܭ௜ሻ൨
 
ܻ = ௠ܸ௔௫ಲ೛೛ · ܺܭ௠ಲ೛೛ + ܺ
 
where Y, X and I denotes average absorbance change per minute, concentration of L-DOPA 
and concentration of DHPCs, respectively. The parameter α determines mechanism, its value 
determines the degree to which the binding of inhibitor changes the affinity of the enzyme for 
substrate. 
Computational Section 
Molecular Docking 
The crystal structure of tyrosinase from A. bisporus (AbTYR) was used as the initial 
point for computational procedures, it was obtained from the Protein Data Bank (PDB) under 
code 2Y9X (23), which contains tropolone (TRO) as a crystal inhibitor. In order to validate 
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the protocol and computational program used for molecular docking simulations for the 
proposed inhibitors, the crystal inhibitor (TRO) was re-docked in the active site of TYR. 
Then, the KA and DHPCs derivatives were submitted for docking calculations. 
The molecular docking procedures were performed using the Molegro Virtual Docker 
(MVD) program (24). It has two docking search algorithms; MolDock Optimizer and 
MolDock SE (Simplex Evolution). The first is the default search algorithm in MVD (25), 
which is based on an evolutionary algorithm. However, MolDock SE performs better on 
some complexes where the standard MolDock algorithm fails (26). Accordingly, for previous 
computational analysis performed for TYR systems, the MolDock SE can be applied with 
success for this type of complex (27). The default parameters for the search algorithm were 
used to carry out molecular docking analysis. The detailed theory behind the MVD program 
and its characteristics are described elsewhere (24, 27). 
 
Results and Discussion 
4H-Chromene Analogues Synthesis 
 The synthesis of the dihydropyrano[3,2-b]chromenediones was successfully achieved 
by employing principles of “green chemistry”, and these included inexpensive off-the-shelf 
catalysts, short reaction times, solvent-free conditions, straightforward work-up, and good-to-
high yielding syntheses (28). 
 
For this study DHPCs were prepared in racemic form (mixture of enantiomers) via a 
three-component condensation reaction of an aromatic aldehyde, dimedone, and KA (28). To 
synthesize DHPC03 and DHPC04, chlorokojic acid (29) was used instead (Scheme 1). All 
compounds were fully characterized by 1H NMR, 13C NMR, IR, HRMS and in some cases X-
ray crystallography (see SI file).  
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Scheme 1. Synthesis of DHPC01 (R=
(R=2-F, X=Cl), and DHPC04 (R=4-F
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Analysis of these kinetics parameters show that the Ki values of three compounds 
were 6.00 µM, 9.00 µM and 4.00 µM for DHPC02, DHPC03 and DHPC04, respectively (see 
Table 1). Therefore, these results show high rates of inhibition of TYR and the order appears 
to be DHPC04 > DHPC02 > DHPC03. 
The increase in the slope of the graph 1/[S] indicated the binding strength of the 
competitive inhibitors. That is, the slope of the graph is increased by the factor (1+ [I] / Ki) in 
the presence of the inhibitor. The kinetic analysis showed that these inhibitors have a single 
inhibition site, possibly with small differences in the docking site. Alternatively, these 
inhibitors can bind in multiple orientations within the catalytic site of the enzyme, giving an 
unexpected interactions, which may reflect small differences in inhibitor affinities.  
The high slope value in the analysis of the variation in Km as a function of inhibitor 
concentration: 22.12 ± 1.98 and r2= 0.98 for DHPC02; 19.92 ± 1.37 and r2= 0.99 for 
DHPC03; and 42.19 ± 7.58 and r2= 0.94 for DHPC04 (see Figure S4), suggests that these 
compounds have a single inhibition site of inhibition. 
Finally, these findings quite reasonably suggest that the DHPC compounds bind to the same 
binding site as the substrate L-DOPA. The results match the values of affinity enzyme-
inhibitor (Ki) and the values of free interaction energy. It is therefore likely that these 
inhibitors present kinetic parameters that show similar features derived from inhibitors with 
chelating and competitive properties (30). 
Molecular Modelling Analysis 
Molecular docking techniques have successfully been used to propose the bind mode 
and interactions occurring between the TYR enzyme and some potential inhibitors, such as, 
isophthalic acid (30), hesperetin (31), oxymatrine (32), hydroxy-based thymol analogues 
(33), KA, and KA analogues (27). In this sense, we have performed similar analyses using 
the DHPC compounds derived from chemical synthesis. In order to validate the molecular 
docking procedure, and the MVD program, a re-docking calculation was computed using the 
crystal inhibitor (TRO) as a reference. Thus, comparing theoretical and experimental 
complexes (TYR-TRO) revealed excellent agreement between theoretical and experimental 
models. In this way, this molecular docking procedure was used to compute the favored 
conformation of the DHPC compounds in the binding site of the AbTYR. 
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According to the re-docking results, the TRO conformation obtained by molecular 
docking was in good agreement with its crystal structure conformation (see Figure S1). 
Furthermore, the DHPC compounds were also submitted to the same molecular docking 
steps. Our results showed that these compounds are complexed to the same binding pocket of 
the TRO inhibitor (see Figure S2), and that the MVD program can reproduce suitable 
conformations for molecular like KA and DHPC compounds in complex with the TYR 
enzyme. 
During the synthesis of the DHPC compounds two enantiomers were obtained for 
each KA derivative (R and S). However, it is not clear at this stage which enantiomer is 
responsible for the TYR activity during kinetic analysis. In order to elucidate this aspect, 
molecular docking calculations using both enantiomers for all the DHPC compounds were 
undertaken. This information was taken into account with respect to the binding affinity 
values, and the interactions between the compounds and the amino acids residues of TYR. 
The binding affinity values obtained through the MOLDOCK scoring function 
showed better affinity for the R enantiomer in all cases (Table 1). The binding affinity values 
for the S enantiomers are provided in the SI file. The orientation of the aryl group for this 
conformation allowed suitable interactions with part of TYR enzyme (Figure 4A). Since the 
aryl group for the S enantiomer was exposed to solvent the interaction with the residues of 
TYR disappeared (Figure 4B). Comparing KA with the DHPC compounds, all molecules 
interacted directly with one copper ion in the catalytic site of TYR as well as the TRO 
inhibitor (Figure 5), which supported the competitive inhibition proposal. Considering that 
DHPC04 had the strongest TYR inhibitory effect, our discussion at this point will be focused 
around this facet, although, it is representative of all other DHPC compounds. 
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Conclusion 
The inhibitory effect of various DHPC compounds were investigated against the TYR 
enzyme, which were found to induce changes in km. This is consistent with competitive 
inhibition interactions with the substrate (L-DOPA) at the active site. Correspondingly, 
changes in Vm indicated binding of the test compounds provided very effective to the 
inhibition of TYR in a competitive inhibitory manner. The inhibitory mechanism of such 
compounds is in accordance with the copper ion chelator concept, in that, analogues to kojic 
acid compete with L-DOPA in the active site,, which induces changes in the hydrophobic 
surfaces. 
Therefore, a combination of inhibition kinetics and computational modeling may 
facilitate the testing of new potential TYR inhibitors and the prediction of their inhibitory 
mechanisms, as shown in the present study. Further biological evaluation of DHPCs and 
detailed toxicity studies are ongoing and will be reported in due course.   
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